FDA Approves Drug-Device Combo to Detect Residual Cancer Aft

FDA Approves Drug-Device Combo to Detect Residual Cancer After Lumpectomy

The FDA has approved Lumisight (pegulicianine), an optical imaging agent, to illuminate residual breast cancer.

Related Keywords

Howard Hechler , Drug Administration , Lumicell Direct Visualization System , Chief Operating Officer ,

© 2025 Vimarsana